Table 2.

Characteristics of extensive chronic GVHD at the time of diagnosis, according to transplant arm

CharacteristicBMT
(n = 32)
PBSCT
(n = 39)
Time to chronic GVHD after transplantation, median d (range) 136  (75-434) 170  (76-539)  
Type of onset, no. (%)   
 Progressive 5  (16) 4  (10)  
 Quiescent 15  (47) 20  (51)  
 De novo 12  (38) 15  (38)  
Platelets < 100 × 109/L, no. (%) 14  (44) 12  (31)  
Treatment with prednisone, no. (%) 11  (34) 13  (33)  
Treatment with other immunosuppressive agents, no. (%) 25  (78) 27  (69) 
Extent of skin involvement, no. (%)   
 None 20  (62) 26  (67)  
 No more than 50% BSA 6  (19) 9  (23)  
 50% or more of BSA 6  (19) 4  (10) 
Presence of any high-risk features, no. (%)* 19  (59) 15  (38)  
 a.
Skin involvement > 50% BSA alone 
2  (6) 2  (5) 
 b.
Platelet count of < 100 × 109/L alone 
11  (34) 9  (23) 
 c.
Progressive-type of onset alone 
1  (3) 1  (3)  
 d.
a plus b or c 
3  (9) 0  (0)  
 e.
a plus b plus c 
1  (3) 2  (5)  
 f.
b and c 
1  (3) 1  (3) 
CharacteristicBMT
(n = 32)
PBSCT
(n = 39)
Time to chronic GVHD after transplantation, median d (range) 136  (75-434) 170  (76-539)  
Type of onset, no. (%)   
 Progressive 5  (16) 4  (10)  
 Quiescent 15  (47) 20  (51)  
 De novo 12  (38) 15  (38)  
Platelets < 100 × 109/L, no. (%) 14  (44) 12  (31)  
Treatment with prednisone, no. (%) 11  (34) 13  (33)  
Treatment with other immunosuppressive agents, no. (%) 25  (78) 27  (69) 
Extent of skin involvement, no. (%)   
 None 20  (62) 26  (67)  
 No more than 50% BSA 6  (19) 9  (23)  
 50% or more of BSA 6  (19) 4  (10) 
Presence of any high-risk features, no. (%)* 19  (59) 15  (38)  
 a.
Skin involvement > 50% BSA alone 
2  (6) 2  (5) 
 b.
Platelet count of < 100 × 109/L alone 
11  (34) 9  (23) 
 c.
Progressive-type of onset alone 
1  (3) 1  (3)  
 d.
a plus b or c 
3  (9) 0  (0)  
 e.
a plus b plus c 
1  (3) 2  (5)  
 f.
b and c 
1  (3) 1  (3) 
*

P = .08.

Close Modal

or Create an Account

Close Modal
Close Modal